gms | German Medical Science

Kongress Medizin und Gesellschaft 2007

17. bis 21.09.2007, Augsburg

Prevalence of risk determinants for metformin-associated lactic acidosis and metformin utilization in the Study of Health in Pomerania

Meeting Abstract

Suche in Medline nach

  • Dietrich Alte - Ernst-Moritz-Arndt-Universität Greifswald, Institut für Community Medicine, Greifswald
  • Sören Runge - Ernst-Moritz-Arndt-Universität Greifswald, Innere Klinik B / Pneumologie, Greifswald
  • Sebastian E. Baumeister - IGES Institut für Gesundheits- und Sozialforschung GmbH, Berlin
  • Henry Völzke - Ernst-Moritz-Arndt-Universität Greifswald, Institut für Community Medicine, Greifswald

Kongress Medizin und Gesellschaft 2007. Augsburg, 17.-21.09.2007. Düsseldorf: German Medical Science GMS Publishing House; 2007. Doc07gmds006

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/gmds2007/07gmds006.shtml

Veröffentlicht: 6. September 2007

© 2007 Alte et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: Risk determinants for the life threatening complication of metformin-associated lactic acidosis are frequently disregarded. The first aim of this study was to investigate the prevalence of currently stated risk determinants in subjects with type 2 diabetes mellitus who use metformin compared to subjects without metformin treatment. The second aim was to estimate the proportion of subjects with alternative drug-treatment who had no risk determinants but would probably benefit from metformin.

Methods: The Study of Health in Pomerania is a population-based health survey including 339 subjects with type 2 diabetes mellitus. Risk determinants were assessed by computer-assisted personal interview and ultrasound.

Results: Among subjects with type 2 diabetes mellitus, n=92 (28.6%) were treated with metformin, n=162 (50.3%) with alternative medication, and n=68 (21.1%) with diet. The prevalence of at least one risk determinant was 62% for the metformin-users. There was no difference regarding number and type of risk determinants. Heart failure, angina pectoris, and liver disorders presented the most frequent risk determinants.

Conclusions: Risk determinants for metformin-associated lactic acidosis are largely disregarded. A better selection of patients can result in a metformin utilization in one forth of subjects on type 2 diabetes mellitus related drug treatment, even without subjects who have risk determinants. A more standardized definition of risk determinants seems to be necessary.